$10.37
+0.01 (+0.10%)
WENN News18 articles
Wendy's Buyout Buzz: 20% Premium Could Value Chain at 9x EBITDA
Wendy's shares jumped 18.4% on reports of a potential Trian-led buyout. A 20% premium would value the chain at roughly 9x EBITDA, though no formal offer has been made.
Wendy's Shares Leap on Potential Trian-Led Buyout
Wendy's shares surged 12% after reports of a potential Trian-led take-private bid, with a 25% premium suggesting a $4.45B enterprise value.
Wendy's Cuts Dividend in Half, Withdraws 2026 Outlook as U.S. Sales Slump
Wendy's halves dividend to $0.07 per share and withdraws 2026 guidance after U.S. same-store sales dropped 7%, far worse than expected. The move frees up about $53.4 million annually.
Alibaba Stock Surges 7% as Qwen AI Model Drives Investor Optimism
Alibaba's stock climbed 7% as the company's Qwen AI model, with a smaller active parameter set, draws attention to its potential for lower inference costs.
Alibaba Stock Retreats After Qwen Surge, Cloud Margins Now Key Focus
Alibaba's stock gave back gains from its Qwen model launch, with weekly declines of 2.5% in the US and 4.3% in Hong Kong. Market attention is now on cloud margins.
Alibaba Shares Jump 3.7% on Qwen3.8 Model, AI Uplift Still Contained
Alibaba (HKG:9988) shares gained 3.73% on Monday following the unveiling of its Qwen3.8 AI model, though the stock's AI premium remained subdued amid broader tech gains.
Alibaba Unveils Qwen3.8-Max-Preview AI Model Amid Apple Partnership Hopes
Alibaba (BABA) introduced Qwen3.8-Max-Preview on Sunday, a 2.4 trillion parameter AI model. ADRs ended the week up 2.35% after an Apple approval surge, but half of Wednesday's gains were lost by Friday's close.
AMD Shares Dip Despite TD Cowen Price Target Hike to $675
AMD shares fell 3.7% despite TD Cowen raising its price target to $675, as investors demand execution. The article covers analyst targets, dilution risks from warrants, and strong data-center growth.
Tianwen-2 Nails Asteroid Navigation, Boosts China Space Stocks by $29.3B
Tianwen-2's optical navigation slashes asteroid position error to ~1 km, lifting three Shanghai-listed space stocks by a combined 29.3 billion yuan on Friday.
Fubo Names Ex-Disney+ Chief Alisa Bowen CEO, Unveils $12.6M Compensation Package
FuboTV appoints former Disney+ president Alisa Bowen as CEO, replacing co-founder David Gandler, with a $12.6 million equity and inducement package disclosed in an SEC filing.
China's Tianwen-2 Probe Captures Asteroid Kamo'oalewa, Origin Debate Heats Up
China's Tianwen-2 probe has imaged asteroid Kamo'oalewa from 20 km away, raising questions about whether it's lunar debris or a weathered asteroid.
Wendy's Shares Surge on Retail Frenzy, Short Squeeze Potential
Wendy's shares jumped 7.1% to $8.42, propelled by retail investors and social media buzz, even as Q1 same-store sales fell 7.8% and net income dropped 42.1%.
Wendy's Stock Surges on Record Volume Amid Short Squeeze and CFO Change
Wendy's stock surged 25.8% on record volume, with short interest at 34% and a new CFO appointed, adding pressure to its turnaround plans.
Wendy's New CFO Takes Helm Amidst High Dividend Yield and Short Seller Scrutiny
Wendy's stock closed up 1.38% at $6.255, with a nearly 9% dividend yield and short interest at 29.67% of float, as new CFO Steve Cirulis focuses on financial discipline amid weak U.S. traffic.
Wendy's New CEO Faces Uphill Battle as Sales Slide Continues
Wendy's same-store sales fell 7.8% in Q1, following an 11.3% Q4 decline. New CEO Robert Wright takes over as the chain closes 164 U.S. locations and faces activist investor pressure.
FBI Probes Crypto Investor Wen Hou's Father Disappearance Amid Fraud Allegations
FBI probes disappearance of Naiping Hou, father of crypto investor Wen Hou, amid cellphone spoofing and fraudulent bank transactions. Soybeans steady despite export sales drop.
BioCryst Shares Slip on New HAE Drug Data, Focus Shifts to Cowen Conference
BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO and targets a late-2027 regulatory submission.
BioCryst Shares Slide on HAE Drug Data, Focus Shifts to Cowen Conference
BioCryst Pharmaceuticals shares fell nearly 3% in premarket trading following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO.